Product Description
a Helicase-Primase Inhibitor, for the Optimal Treatment of Herpes Zoster (Sourced from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8402822/)
Mechanisms of Action: HP Inhibitor
Novel Mechanism: Yes
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: Japan
Approved Indications: None
Known Adverse Events: None
Company: Maruho
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic: Japan
Active Clinical Trial Count: 1
Highest Development Phases
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| JapicCTI-184242 | P1 |
Active |
Unknown |
2019-11-30 |